Introduction
============

Asthma is a chronic inflammatory disorder of the airways that causes recurrent episodes of wheezing, breathlessness, tightness of the chest, and coughing, especially at night or in the morning. These symptoms usually are associated with impaired lung function, frequent use of rescue medication, nighttime symptoms, hospital admissions, near fatal episodes, and limitation of daily activities.[@b1-ppa-8-263] Patients with more than a mild form of asthma require daily prophylactic asthma medications to reverse airway inflammation and control the asthma severity.[@b2-ppa-8-263] The estimated prevalence of asthma among children up to 14 years old in Malaysia is 4.5%.[@b3-ppa-8-263]

Nonadherence to treatment is one important factor in poor asthma control.[@b4-ppa-8-263] Asthmatic children with uncontrolled asthma are more likely to be hospitalized for asthma and require mechanical ventilation, and are at greater risk for recurrent hospitalization than are children whose asthma is well controlled.[@b5-ppa-8-263] The nonadherence rate to asthma treatments has been reported to be as high as 75% in some European countries and is recognized as the main cause of poor asthma control.[@b6-ppa-8-263]

Although treatment adherence is recognized as crucial in the management of children with chronic illnesses, the tools used by clinicians to identify adherence in asthmatic children are limited. Pharmacy databases are increasingly being used to assess medication usage, and a number of measures have been developed to characterize both the intensity of medication usage via intended use (adherence), and the extent to which such usage persists over time (persistence).[@b7-ppa-8-263] Information on prescription refills obtained from computerized pharmacy prescription records gives an indication of the level of adherence over a specific time frame, assuming that the patient consumes the dispensed medication and does not obtain the medication at a nonrecording pharmacy.[@b8-ppa-8-263],[@b9-ppa-8-263]

However, there is lack of uniformity in the definitions used to describe the concepts of medication adherence or persistence. Medication adherence generally refers to the act of conforming to recommendations made by the health care provider, with respect to the timing and frequency of taking medication as well as the dosage.[@b10-ppa-8-263] In retrospective studies, medication adherence can be measured as the number of doses dispensed in relation to the dispensing period and characterized by the medication possession ratio (MPR). The MPR measurement determines patient adherence with a cutoff point of 80% of medication refilled. On the other hand, persistence is defined as continuing to take any amount of the medication. Assessing persistence is practical for use in both prospective and retrospective studies because it measures from the treatment initiation point to the end of the observation period. An analysis of persistence is typically based on the number of days allowed between refills, considered the "permissible gap," and is characterized by the continuous measure of gaps (CMG).[@b10-ppa-8-263]

Controlled asthma is characterized by minimal or no symptoms during the day and at night, no asthma attacks, no emergency visits to physicians or hospitals, minimal need for rescue medications, no limitations on physical activities and exercise, nearly normal lung function, and minimal or no medication side effects.[@b11-ppa-8-263] Poor control of asthma may be the result of chronic undertreatment of the disease and greater reliance on the reliever medications for the relief of acute asthma symptoms.[@b4-ppa-8-263] Previous study has shown an association between poor asthma management, frequent hospital admissions, and poor lung function. There is evidence to show that the prevalence and severity of symptoms and rates of hospital admission for children with asthma are increasing in many countries due to nonadherence to prescribed medications.[@b12-ppa-8-263] Furthermore, the relatively high admission and readmission rates for children with asthma are a concern.[@b13-ppa-8-263]

The primary aim of this study was to retrospectively review pharmacy refills of preventive medications in asthmatic children and use the calculated MPR and CMG to determine medication adherence and persistence, respectively. Demographic data, including age, sex, and ethnicity, together with the presence of comorbidities, number of preventive medications, and duration of asthma diagnoses were investigated to identify predictors of nonadherence.

Methodology
===========

This study was a nonexperimental, retrospective study conducted at the Universiti Kebangsaaan Malaysia Medical Centre (UKMMC), Kuala Lampur, Malaysia. The participants included asthmatic children who were outpatients at the Pediatric Clinic 2 at UKMMC from January 1 to December 31, 2011. This study was approved by the Research Ethics Committee of UKMMC (UKM 1.5.3.5/244/NF-029-2012).

Patient selection criteria
--------------------------

The inclusion criteria for patients in the present study were as follows: age of less than or equal to 18 years; primary diagnosis of bronchial asthma in a medical or outpatient claims file; history of asthma for at least 1 year; attended the outpatient Pediatric Clinic at UKMMC; had at least one prescription of any preventive medication refilled within the 1-year period from January until December 2011. These patients were excluded: patients with incomplete dispensing or medical data; patients with asthma diagnosed as a secondary disease; patients who were hospitalized most of the time.

Sampling methods
----------------

This was a retrospective observational study, with convenience sampling used in the patient selection process. The data collection occurred in two phases: first, data regarding prescription dispensing were collected at the outpatient pharmacy department, and second, data from medical records were obtained from the Medical Records department at UKMMC.

Research instruments
--------------------

### Patient medical record

The patient data were collected and recorded using a data collection form. The collected demographic data included age, sex, and ethnicity. The clinical data included disease duration, type of preventive medications, number of preventive medications, disease severity, and the presence of comorbidities.

The data collected regarding medications were based on the types of preventive medications prescribed to asthmatic children, with reference to the UKMMC's Drug Formulary. Among the types of preventive medications collected from the pharmacy dispensing database were corticosteroids: budesonide (Pulmicort^®^ \[AstraZeneca, London, UK\], Giona^®^ Easyhaler \[Orion Corp, Espoo, Finland\]), beclomethasone dipropionate (Becotide^®^ Evohaler \[GlaxoSmithKline, Inc, Brentford, UK\], Beclomet Easyhaler^®^ \[Orion Corp\]), and ciclesonide (Alvesco^®^ \[Takeda Pharmaceuticals International GmbH, Zurich, Switzerland\]); leukotriene receptor antagonist: montelukast (Singulair^®^ \[Merck and Co, Inc, Whitehouse Station, NJ, USA\]); and combination therapy: fluticasone plus salmeterol (Seretide^®^ \[GlaxoSmithKline, Inc\]), budesonide plus formoterol (Symbicort^®^ \[AstraZeneca\]), ipratropium plus fenoterol (Berodual-N^®^ \[Boehringer Ingelheim Gmbh, Ingelheim, Germany\]), and ipratropium plus salbutamol (Combivent^®^ \[Boehringer Ingelheim Gmbh\]).

Medication refill records
-------------------------

Adherence to preventive asthma medications was assessed by measuring refill behavior to calculate the adherence and persistence. The refill adherence was measured using the MPR. MPR determines the number of skipped doses and the discontinuation of medications by assessing medication availability, based on the following equation:[@b14-ppa-8-263]
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MPR does not address medication overuse; therefore, the resulting value may exceed 100%.[@b15-ppa-8-263]

Medication persistence was measured using the CMG, which quantifies the gaps between prescription refills over multiple refill intervals, calculated as follows:[@b16-ppa-8-263]

CMG
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Computation of the CMG takes oversupply into account, therefore, the resulting value cannot exceed 1.[@b16-ppa-8-263] The MPR and CMG are both indirect measures that indicate overall patient adherence. The data regarding medication refills and dispensing were collected from the pharmacy dispensing database in the outpatient department (OPD).

Statistical analysis
--------------------

Analyses of the demographic and clinical data were conducted using descriptive analysis. The adherence results were analyzed as MPR and CMG, both in categories and as continuous measures. The patients were classified as adherent when the MPR was ≥80% and nonadherent when the MPR was \<80%. Likewise, patients with a CMG of ≤20% were considered persistent, whereas a CMG of \>20% indicated nonpersistence.[@b17-ppa-8-263] Using McNemar's test, we then analyzed an independent model of the association between MPR and CMG; further analysis was conducted using the kappa coefficient (*κ*).

Demographic (age, sex, and ethnicity) and clinical data (comorbidities, number of preventive medications, and duration of asthma diagnosis) were included as independent factors in a logistic regression, to determine the significant predictors for adherence (MPR) and persistence (CMG). Odds ratios (ORs) and 95% confidence intervals (CIs) were calculated for this regression.

SPSS (SPSS Inc. PASW Statistics for Windows, Version 18.0 \[2009\]; Chicago, IL, USA) was used for analyses. All reported *P*-values were two-sided, with *P*\<0.05 considered statistically significant.

Results
=======

Patient characteristics
-----------------------

A total of 550 subjects were identified from the UKMMC pharmacy database as having preventive medications refilled within the study period (January 1, 2011--December 31, 2011). Of these, 373 subjects who fulfilled the inclusion criteria were randomly selected. Finally, 155 subjects who only filled their prescription once (ie, no refill prescription) were excluded from the study, leaving 218 participants in the sample of data to be analyzed. The corticosteroid inhalers were the most frequently refilled medication (44.3%), followed by the leukotriene receptor antagonists (22.3%). The mean (standard deviation \[SD\]) age of subjects was 8.05 (3.9) years, and more than half (58.7%) were male. A majority of subjects were Malays (83.5%). A total of 147 (67.4%) subjects had a family history of bronchial asthma. The mean number of comorbidities was 1.17 (1.0). The mean duration of asthma was 5.02 (2.9) years, and an average of 1.3 (0.5) types of preventive medications were prescribed for each patient. The characteristics of the study population are summarized in [Table 1](#t1-ppa-8-263){ref-type="table"}.

Prevalence of nonadherence
--------------------------

Overall, adherence was poor, with only 38.1% of the subjects having an MPR of ≥80%. Multiple termination gaps within the study period were discovered, and based on the CMG scores, only 27.5% of the subjects were persistent with their medication.

Relationship between adherence and persistence
----------------------------------------------

The relationship between adherence and persistence was explored through McNemar's test, as shown in [Table 2](#t2-ppa-8-263){ref-type="table"}. Our findings suggest that refill adherence was significantly different from refill persistence, and the relationship between adherence and persistence was weak (*P*\<0.001; *κ*=0.379).

Predictors of medication adherence and persistence
--------------------------------------------------

A binary logistic regression was performed to determine factors that may influence adherence and persistence. It was found that age, sex, ethnicity, number of preventive medications refilled, and the duration of the asthma diagnosis were not significant predictors of adherence or persistence. Only the presence of comorbidities was found to significantly influence adherence and persistence (OR 16.2, 95% CI: 7.76--33.84 and OR 2.6, 95% CI: 0.134--52.79, respectively \[*P*\<0.001\]), as shown in [Tables 3](#t3-ppa-8-263){ref-type="table"} and [4](#t4-ppa-8-263){ref-type="table"}.

Discussion
==========

In this study, only 38.1% (or 83 of 218 children with asthma) were adherent to the preventive medications, based on a score of MPR ≥80%. This is consistent with previous research, in which 15%--39% of asthmatic children aged 0--18 years were adherent to the use of controller medications.[@b18-ppa-8-263] It has been suggested that low adherence among children with asthma may be due to parental inability to take time off from work to attend appointments and refill their child's medications.[@b19-ppa-8-263] In addition, Dawood et al mentioned that, in general, poor adherence in children can be attributed to the parental lack of understanding about the diagnosis and drug therapy effectiveness as well as fear of medication side effects.[@b20-ppa-8-263]

We also observed a relatively low level of persistence (27.5%). Previous research regarding persistence with asthma inhaler medications discovered that poor persistence among children was associated with their incomplete understanding of the mechanism of action of their preventive medicines, thus causing them to stop the medications when they felt better rather than using them as intended.[@b21-ppa-8-263] It also has been reported that children will stop using medication when they think the treatment has not helped improve their asthma over a long period, even when the actual reason for poor treatment response could be due to improper use of the medication (eg, poor inhalation technique).[@b22-ppa-8-263]

The relationship between adherence and persistence was found to be significant (*P*\<0.001) but weak (*κ*=0.379) (a kappa value of between 0.21 and 0.40 is classified as fair agreement).[@b23-ppa-8-263] A total of 65.6% patients had dissimilar classifications of adherence and persistence. Only 34.4% of patients in this study were classified as nonadherent and nonpersistent ([Table 2](#t2-ppa-8-263){ref-type="table"}). This could be explained by the fact that adherence and persistence measure different aspects of medication-taking behavior. MPR is defined by the "number of doses dispensed in relation to the dispensing period," whereas CMG is defined as the "duration of time from initiation to the discontinuation of therapy."[@b10-ppa-8-263] Hence, patients may be refilling the prescriptions regularly but may not be persistent in taking their medicines.

This is consistent with results of a study by Lee et al, which demonstrated that medication adherence was significantly and positively associated with persistence, according to data from pharmacy claims system.[@b24-ppa-8-263] Elliot et al studied medication adherence and persistence from an economic perspective, stating that both are consistently affected by age, experiences, and side effects and furthermore, that these relationships change over time.[@b25-ppa-8-263]

Predictors of adherence
-----------------------

The possible predisposing characteristics assessed in this study were age, ethnicity, sex, the presence of comorbidities, duration of the asthma diagnosis, and the number of preventive medications refilled. We found that child age was not a significant predictor of adherence or persistence, consistent with the results of a study by Lindberg et al.[@b26-ppa-8-263] However, other studies have found an association between child age and adherence levels.[@b27-ppa-8-263],[@b28-ppa-8-263] While parents are fully responsible for administering medications to their young children, this is not the case for adolescents.[@b29-ppa-8-263] Adolescents are driven by the need for peer acceptance, rather than parental control, and adherence to a medication regimen may place them at risk of being different from others.[@b30-ppa-8-263]

We also found no association between participant sex and adherence or persistence levels. Similar results were noted in studies by Bae et al and Vic et al; however, Balbay et al found that males had poorer adherence and persistence levels compared with females.[@b31-ppa-8-263]--[@b33-ppa-8-263] Conversely, Elkout et al discovered higher adherence rates in males than in females. Thus, the association between sex and adherence remains unclear.[@b18-ppa-8-263]

In the present study, we also found no significant relationship between ethnicity and adherence or persistence levels. Malaysian citizens consist of the ethnic groups Malays (63.1%), Chinese (24.6%), Indians (7.3%), and others (5%).[@b34-ppa-8-263] Therefore, the ethnic composition may not have been represented in a similar proportion in this study, as shown in [Table 1](#t1-ppa-8-263){ref-type="table"}, and may have affected the findings. Nsouli suggested that there is a relationship between treatment adherence and race, and that the low socioeconomic status and the language barriers of the minority races in the countries investigated resulted in poorer adherence.[@b35-ppa-8-263] However, Jin et al concluded that race may not be a true predictive factor of poor adherence, due to the inconsistent results in the research literature.[@b36-ppa-8-263]

Furthermore, the duration of asthma diagnosis had no association with adherence or persistence levels. According to a study by Singh et al, longer disease durations may motivate patients to search for complementary therapies as "magic cures," due to the perception that the lack of improvement in their asthma symptoms is due to the ineffectiveness of their current treatment.[@b37-ppa-8-263] To the contrary, Latty et al studied adherence to asthma inhalers and leukotriene receptor antagonists and found that 12-month persistence rates were lower in new medications users (1.5%--6%) than in chronic medication users (27%--44%).[@b38-ppa-8-263] This suggests that perhaps, after years of suffering from asthma, patients may be more likely to accept and follow prescribed treatment regimens.[@b36-ppa-8-263]

Inhaled corticosteroids were the most commonly prescribed preventive medications in our study, which is to be expected -- they are generally a first-line maintenance therapy because of their significant improvement in asthma control.[@b39-ppa-8-263] However, our results suggest no association between the number of prescribed preventive medications and adherence or persistence levels. This is in contrast to Joseph et al, who found that the number of medications prescribed played a significant role in medication adherence and persistence.[@b40-ppa-8-263] When patients need to consume many medications at once, they will weigh potential risks against the benefits. Consequently, they may hesitate or be nonadherent to their prescribed medications when their perceived risks outweigh the perceived benefits.[@b41-ppa-8-263] No association was found for this variable, possibly due to the fact that only the number of preventive medications and not the total number of prescribed medications were analyzed as a possible predictor of nonadherence in the present study.

Presence of comorbidities was the only factor significantly associated with adherence and persistence levels among children with asthma in this study. However, the data suggested two different directions of association: the presence of comorbidity reduced the risk of nonadherence but increased the risk of nonpersistence. Boulet found that comorbidities were associated with uncontrolled asthma.[@b42-ppa-8-263] The presence of comorbidities may worsen asthma severity, thus making asthma control more difficult to achieve. Children's behavior regarding asthma medications may also change when they have comorbid illness.[@b42-ppa-8-263] Furthermore, fluctuations in asthma control and the frequent presentation of asthma symptoms in patients with comorbidities can result in the perception of ineffective treatment.[@b43-ppa-8-263] Consequently, children tend to discontinue medications themselves, resulting in low persistence levels.

Study limitations
-----------------

The present study only collected data for a 1-year period, which was rather short, and results might differ if adherence and persistence were examined for a longer time frame. Furthermore, the sample size was relatively small, although larger than many other studies in this area. This may have resulted in a reduced number of predictors that could potentially influence adherence in this population. Estimating prescription refill adherence via a pharmacy database may not reflect the actual prescribing and dispensing of medications or the use of these medications by the children themselves. It is also assumed that the patients did not obtain their medications at other pharmacies, which we believe was the case for the majority of patients in this study. This is because the payment at the hospital is fixed at RM40 (US\$12.16) per patient for each clinic visit, inclusive of all medications prescribed that are listed in the hospital's formulary (this is the case for all the asthma preventive medications mentioned in this study). However, medication is free for government employees and their dependants at the study site (UKMMC) and all other government hospitals. The nature of the study, being retrospective, is also a limitation, and it was also assumed that the pharmacy kept a good and reliable database for the medication refills of all patients. Future studies would benefit from including a larger sample size and measuring adherence, at various time points, for more than a 1-year period.

Conclusion
==========

Asthmatic children at the UKMMC had poor adherence and persistence to preventive asthma medications. Presence of comorbidities was the only factor found to significantly predict medication adherence in children with asthma. Proper evaluation and management of comorbid conditions among asthmatic children is essential to achieve better adherence to medication and better control of the disease.
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###### 

Characteristics of study sample (n=218)

  Characteristics (n=218)                          Findings     
  ------------------------------------------------ ------------ -------------
  Age (years)                                                   8.05±3.93
   1--6                                            84 (38.5)    
   7--12                                           100 (45.9)   
   13--18                                          34 (15.6)    
  Sex                                                           
   Male                                            128 (58.7)   
   Female                                          90 (41.3)    
  Ethnicity                                                     
   Malay                                           182 (83.5)   
   Chinese                                         19 (8.7)     
   Indian                                          13 (6.0)     
   Others                                          4 (1.8)      
  **Comorbidities**                                             
  Presence of comorbidity                                       
   Yes                                             159 (72.9)   
   No                                              59 (27.1)    
   Total number                                    251          1.17±1.00
   Allergy rhinitis                                74 (29.5)    per patient
   Eczema                                          46 (18.3)    
   Obesity                                         22 (8.8)     
   Allergy                                         5 (2.0)      
   Acute bronchitis                                4 (1.6)      
   Pneumonia                                       2 (\<1)      
   Others                                          98 (39.0)    
  Family background of asthma                                   
   Yes                                             147 (67.4)   
   No                                              63 (28.9)    
   Adopted                                         8 (3.7)      
  Duration of asthma diagnosis (years)                          
   1--6                                            112 (51.4)   5.02±2.90
   7--12                                           91 (41.7)    
   13--18                                          15 (6.9)     
  Preventive medications refilled                               
   Total number                                    294          1.30±0.46
  Type of preventive medications                                
   Budesonide (Pulmicort^®^)                       127 (44.3)   
   Montelukast (Singulair^®^)                      64 (22.3)    
   Ciclesonide (Alvesco^®^)                        31 (10.8)    
   Fluticasone + salmeterol (Seretide^®^ 25/125)   31 (10.8)    
   Budesonide (Giona^®^ Easyhaler)                 24 (8.4)     
   Beclomethasone (Becotide^®^ Evohaler)           4 (1.4)      
   Beclomethasone (Beclomet Easyhaler^®^)          4 (1.4)      
   Others                                          2 (\<1)      

**Notes:** Budesonide (Pulmicort^®^ \[AstraZeneca, London, UK\], Giona^®^ Easyhaler \[Orion Corp, Espoo, Finland\]), beclomethasone dipropionate (Becotide^®^ Evohaler \[GlaxoSmithKline, Inc, Brentford, UK\], Beclomet Easyhaler^®^ \[Orion Corp\]), ciclesonide (Alvesco^®^ \[Takeda Pharmaceuticals International GmbH, Zurich, Switzerland\]), montelukast (Singulair^®^ \[Merck and Co, Inc, Whitehouse Station, NJ, USA\]), fluticasone + salmeterol (Seretide^®^ \[GlaxoSmithKline, Inc\]).

**Abbreviation:** SD, standard deviation.

###### 

Association of two pharmacy refill measures (MPR and CMG)

  Total (n=218)          MPR          McNemar's test of *χ*^2^ 2-tailed test *P*-value   Measure of agreement *κ*                            
  ---------------------- ------------ -------------------------------------------------- --------------------------------------------------- -------
  CMG                                                                                                                                        
   Persistent ≤20%       60 (27.5%)   0 (0%)                                             \<0.001[\*](#tfn4-ppa-8-263){ref-type="table-fn"}   0.397
   Nonpersistent \>20%   75 (34.4%)   83 (38.1%)                                                                                             

**Notes:** The values are presented as patient mean (percentage).

*P*\<0.05.

**Abbreviations:** CMG, continuous measure of gaps; MPR, medication possession ratio.

###### 

Factors in the logistic regression analysis models that are independently linked to adherence

  Parameter                                Log odds (B)   SE      2-tailed test *P*-value                             OR       95% CI   
  ---------------------------------------- -------------- ------- --------------------------------------------------- -------- -------- --------
  Presence of comorbidities                                                                                                             
   Yes                                     2.786          0.376   \<0.001[\*](#tfn7-ppa-8-263){ref-type="table-fn"}   16.209   7.763    33.844
   No                                                                                                                                   
  (Reference category: No comorbidities)                                                                                                

**Notes:** Dependent variable coding: MPR \<80% (nonadherence) =0; MPR ≥80% (adherence) =1.

*P*\<0.05; B - regression coefficient.

**Abbreviations:** CI, confidence interval; MPR, medication possession ratio; OR, odds ratio; SE, standard error.

###### 

Factors in the logistic regression analysis models that are independently linked to nonpersistence

  Parameter                                Log odds (B)   SE      2-tailed test *P*-value                              OR      95% CI   
  ---------------------------------------- -------------- ------- ---------------------------------------------------- ------- -------- -------
  Presence of comorbidities                                                                                                             
   Yes                                     0.968          1.520   \<0.001[\*](#tfn10-ppa-8-263){ref-type="table-fn"}   2.633   0.134    52.79
   No                                                                                                                                   
  (Reference category: No comorbidities)                                                                                                

**Notes:** Dependent variable coding: CMG ≤20% (persistence) =0; CMG \>20% (nonpersistence) =1.

*P*\<0.05.

**Abbreviations:** CI, confidence interval; CMG, continuous measure of gaps; OR, odds ratio; SE, standard error.
